New Outperform Rating Was Given to Assembly Biosciences (NASDAQ:ASMB)

August 9, 2018 - By Mark Babin

Why Has Baird Given Assembly Biosciences (NASDAQ:ASMB) a $74 Price Target

Baird analyst started coverage with a Outperform rating on Assembly Biosciences (NASDAQ:ASMB) today and set a price target of $74. The company’s shares opened today at 42.61.

Assembly Biosciences, Inc. (NASDAQ:ASMB) Ratings Coverage

Among 4 analysts covering Assembly Biosciences (NASDAQ:ASMB), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Assembly Biosciences has $8400 highest and $4200 lowest target. $66.67’s average target is 56.47% above currents $42.61 stock price. Assembly Biosciences had 6 analyst reports since March 9, 2018 according to SRatingsIntel. FBR Capital maintained the stock with “Neutral” rating in Tuesday, May 8 report. The rating was downgraded by Chardan Capital Markets on Friday, April 13 to “Neutral”. The rating was maintained by FBR Capital with “Hold” on Friday, March 9. The rating was maintained by FBR Capital with “Hold” on Thursday, June 21.

The stock increased 1.77% or $0.74 during the last trading session, reaching $42.61. About 113,861 shares traded. Assembly Biosciences, Inc. (NASDAQ:ASMB) has risen 70.43% since August 9, 2017 and is uptrending. It has outperformed by 57.86% the S&P500.

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. The company has market cap of $1.07 billion. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. It currently has negative earnings. The firm also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract.

More notable recent Assembly Biosciences, Inc. (NASDAQ:ASMB) news were published by: Benzinga.com which released: “44 Biggest Movers From Yesterday” on July 13, 2018, also Globenewswire.com with their article: “Assembly Biosciences Announces Second Quarter 2018 Financial Results” published on August 08, 2018, Streetinsider.com published: “UPDATE: Baird Starts Assembly Biosciences (ASMB) at Outperform” on August 07, 2018. More interesting news about Assembly Biosciences, Inc. (NASDAQ:ASMB) were released by: Nasdaq.com and their article: “Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B …” published on July 25, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares” with publication date: July 11, 2018.

Assembly Biosciences, Inc. (NASDAQ:ASMB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.